comprehensive -WSS

comprehensive

author：entertainment 2025-10-02 13:01:37 - browse：67

Outgoing Bristol CEO Giovanni Caforio Emilie Pickering for STAT

It’s changing of the guard time at pharmaceutical giant Bristol Myers Squibb. On Wednesday, CEO Giovanni Caforio will step down. He’ll be replaced by Christopher Boerner, who is currently chief operating officer.

When Caforio took over in May 2015, Bristol was known as a big pharmaceutical firm with the high-flying stock of a biotechnology company, largely due to its role as the company that brought cancer immunotherapy to market. But Bristol stumbled in 2016 when its immunotherapy Opdivo failed to help patients with non-small cell cancer more than chemotherapy. Opdivo remained a big seller, but its failure allowed Merck’s rival Keytruda to move into position to become the best-selling medicine in the world. In 2019, Caforio tried to flip the script, buying the biotech Celgene for $74 billion.

STAT recently sat down with Caforio, 59, to look back on what went wrong and right with his tenure. He also reflected on what it meant to be a physician — and the son of a physician. “We were speaking about patient stories over lunch and dinner, when I was a kid, and I think that drove my passion for medicine,” he said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： ASCO Takeaways: Winners, snoozers, and the art of cancer care

WSS

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

FTC loses bid to block Novant's North Carolina hospital merger

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

CMS got Medicare Advantage quality rating wrong, judge rules

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Readout Newsletter: Bristol, Sangamo, Gilead, and more

hotspot

comprehensive

Wikipedia

DIEP, the 'gold standard' of breast reconstruction, is under threat

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Bright Health sells Medicare Advantage business to Molina

UCLA team creates talking throat patch for voice disorders

Novavax promises a turnaround & Lilly roils the obesity market

Amid AI frenzy, a top HHS official's quest to create safeguards

Psychedelics group wrestles with new pharma identity

Stopping antidepressants leads to symptoms for 1 in 6 patients

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

How many hemophilia patients actually want gene therapy?

focus

Male and female sex labels in research insufficient, scientists say

Why scientists need input from humanists on sensitive research

Readout Newsletter: CAR

EPA limits use of carcinogenic gas for sterilizing medical devices

Ebola: Gilead Sciences antiviral shows promise as new treatment

Stopping antidepressants leads to symptoms for 1 in 6 patients

Wikipedia

hotspot

focus

leisure time